Enfermedades Infecciosas

Buscador de publicaciones

Sólo se han incluido artículos originales, editoriales y revisiones.

Blanco JR, Alejos B, Moreno S.

Impact of dolutegravir and efavirenz on immune recovery markers: results from a randomized clinical trial.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2018. 24(8): 900-907. Nº de citas: 9

[doi:10.1016/j.cmi.2017.11.016]
Cuypers L, Pérez AB, Chueca N, Aldamiz-Echevarría T, Alados JC, Martínez-Sapiña AM, Merino D, Pineda JA, Téllez F, Espinosa N, Salméron J, Rivero-Juarez A, Vivancos MJ, Hontañón V, Vandamme AM, García F.

Relapse or reinfection after failing hepatitis C direct acting antiviral treatment: Unravelled by phylogenetic analysis.

Plos One 2018. 13(7): . Nº de citas: 7

[doi:10.1371/journal.pone.0201268]
Fortún J, Gioia F, Muñoz P, Graus J, Gómez-García de la Pedrosa E, Martín-Dávila P, Saiz A, Vena A, Moreno S.

T2 magnetic resonance for the diagnosis of deep-seated invasive candidiasis in a liver recipient without candidemia.

REVISTA IBEROAMERICANA DE MICOLOGIA 2018. 35(3): 159-161.

[doi:10.1016/j.riam.2018.03.002]
Páez-Vega A, Poyato A, Rodriguez-Benot A, Guirado L, Fortún J, Len O, Abdala E, Fariñas MC, Cordero E, de Gracia C, Hernández D, González R, Torre-Cisneros J, Cantisán S, Spanish Network for Research in Infectious Diseases (REIPI) (RD16/0016), Spanish Renal Disease Network (REDinREN, RD16/0009).

Analysis of spontaneous resolution of cytomegalovirus replication after transplantation in CMV-seropositive patients with pretransplant CD8+IFNG+ response.

ANTIVIRAL RESEARCH 2018. 155: 97-105. Nº de citas: 4

[doi:10.1016/j.antiviral.2018.05.006]
Berenguer J, Gil-Martin Á, Jarrin I, Moreno A, Dominguez L, Montes M, Aldámiz-Echevarría T, Téllez MJ, Santos I, Benitez L, Sanz J, Ryan P, Gaspar G, Alvarez B, Losa JE, Torres-Perea R, Barros C, San Martin JV, Arponen S, de Guzmán MT, Monsalvo R, Vegas A, Garcia-Benayas MT, Serrano R, Gotuzzo L, Menendez MA, Belda LM, Malmierca E, Calvo MJ, Cruz-Martos E, González-García JJ.

All-oral direct-acting antiviral therapy against hepatitis C virus (HCV) in human immunodeficiency virus/HCV-coinfected subjects in real-world practice: Madrid coinfection registry findings.

HEPATOLOGY 2018. 68(1): 32-47. Nº de citas: 44

[doi:10.1002/hep.29814]
Zegri-Reiriz I, de Alarcón A, Muñoz P, Martínez Sellés M, González-Ramallo V, Miro JM, Falces C, Gonzalez Rico C, Kortajarena Urkola X, Lepe JA, Rodriguez Alvarez R, Reguera Iglesias JM, Navas E, Dominguez F, Garcia-Pavia P.

Infective Endocarditis in Patients With Bicuspid Aortic Valve or Mitral Valve Prolapse.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY 2018. 71(24): 2731-2740. Nº de citas: 39

[doi:10.1016/j.jacc.2018.03.534]
Deusch S, Serrano-Villar S, Rojo D, Martínez-Martínez M, Bargiela R, Vázquez-Castellanos JF, Sainz T, Barbas C, Moya A, Moreno S, Gosalbes MJ, Estrada V, Seifert J, Ferrer M.

Effects of HIV, antiretroviral therapy and prebiotics on the active fraction of the gut microbiota.

AIDS 2018. 32(10): 1229-1237. Nº de citas: 15

[doi:10.1097/QAD.0000000000001831]
Valencia J, Ryan P, Alvaro-Meca A, Troya J, Gutierrez J, Cuevas G, Moreno S.

High HIV seroconversion rate in hepatitis C virus-infected drug users followed in a harm reduction unit: a lost opportunity for preexposure prophylaxis.

AIDS 2018. 32(9): 1157-1163. Nº de citas: 1

[doi:10.1097/QAD.0000000000001806]
Casado JL, Monsalvo M, Rojo AM, Fontecha M, Rodriguez-Sagrado MA.

Dolutegravir and rilpivirine for the maintenance treatment of virologically suppressed HIV-1 infection.

EXPERT REVIEW OF CLINICAL PHARMACOLOGY 2018. 11(6): 561-570.

[doi:10.1080/17512433.2018.1478726]
Aguado R, Páez-Vega A, Agüera ML, Montejo M, Guirado L, Fortún J, Suárez-Benjumea A, Len O, Fariñas MC, de Gracia C, Hernández D, Cobos-Ceballos MJ, Torre-Cisneros J, Cantisán S.

Lack of evidence of association between IFNG and IL28B polymorphisms and QuantiFERON-CMV test results in seropositive transplant patients.

HUMAN IMMUNOLOGY 2018. 79(6): 499-505. Nº de citas: 3

[doi:10.1016/j.humimm.2018.03.009]
Reinwald M, Silva JT, Mueller NJ, Fortún J, Garzoni C, de Fijter JW, Fernández-Ruiz M, Grossi P, Aguado JM.

ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Intracellular signaling pathways: tyrosine kinase and mTOR inhibitors).

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2018. 24 Suppl 2: 53-70. Nº de citas: 83

[doi:10.1016/j.cmi.2018.02.009]
Cascajero A, Rastrojo A, Díez-Fuertes F, Hernández-Novoa B, Aguado B, Moreno S, Alcami J, Pérez-Olmeda M.

Deep-Sequencing Analysis of the Dynamics of HIV-1 Quasiespecies in Naive Patients during a Short Exposure to Maraviroc.

JOURNAL OF VIROLOGY 2018. 92(11): . Nº de citas: 2

[doi:10.1128/JVI.00390-18]
Domínguez-Alegría AR, Pintado V, Barbolla I.

Treatment and prevention of invasive pneumococcal disease.

REVISTA CLINICA ESPANOLA 2018. 218(5): 244-252. Nº de citas: 6

[doi:10.1016/j.rce.2018.01.004]
Medrano LM, Garcia-Broncano P, Berenguer J, González-García J, Jiménez-Sousa MÁ, Guardiola JM, Crespo M, Quereda C, Sanz J, Canorea I, Carrero A, Hontañón V, Muñoz-Fernández MÁ, Resino S, and the GESIDA 3603b Study Group.

Elevated liver stiffness is linked to increased biomarkers of inflammation and immune activation in HIV/hepatitis C virus-coinfected patients.

AIDS 2018. 32(9): 1095-1105. Nº de citas: 21

[doi:10.1097/QAD.0000000000001787]
Ndumbi P, Del Romero J, Pulido F, Velasco Arribas M, Dronda F, Blanco Ramos JR, García de Olalla P, Ocaña I, Belda-Ibañez J, Del Amo J, Álvarez-Del Arco D, aMASE Research Group.

Barriers to health care services for migrants living with HIV in Spain.

EUROPEAN JOURNAL OF PUBLIC HEALTH 2018. 28(3): 451-457. Nº de citas: 11

[doi:10.1093/eurpub/ckx225]
Navarro M, Navaza B, Guionnet A, López-Vélez R.

Overcoming Barriers to HIV Prevention and Healthcare Among Sub-Saharan African Migrants in Spain.

Jmir Public Health And Surveillance 2018. 4(2): 10478-10478.

[doi:10.2196/10478]
Llop M, Sifuentes WA, Bañón S, Macia-Villa C, Perez-Elías MJ, Rosillo M, Moreno S, Vázquez M, Casado JL.

Increased prevalence of asymptomatic vertebral fractures in HIV-infected patients over 50 years of age.

Archives Of Osteoporosis 2018. 13(1): 56-56. Nº de citas: 6

[doi:10.1007/s11657-018-0464-2]
Madrid-Elena N, García-Bermejo ML, Serrano-Villar S, Díaz-de Santiago A, Sastre B, Gutiérrez C, Dronda F, Coronel Díaz M, Domínguez E, López-Huertas MR, Hernández-Novoa B, Moreno S.

Maraviroc Is Associated with Latent HIV-1 Reactivation through NF-?B Activation in Resting CD4 + T Cells from HIV-Infected Individuals on Suppressive Antiretroviral Therapy.

JOURNAL OF VIROLOGY 2018. 92(9): . Nº de citas: 32

[doi:10.1128/JVI.01931-17]

Instituto Ramón y Cajal de investigación sanitaria

Unidades centrales de apoyo

Otros servicios científico-técnicos

Enfermedades Infecciosas

Buscador de publicaciones

Impact of dolutegravir and efavirenz on immune recovery markers: results from a randomized clinical trial.

Relapse or reinfection after failing hepatitis C direct acting antiviral treatment: Unravelled by phylogenetic analysis.

T2 magnetic resonance for the diagnosis of deep-seated invasive candidiasis in a liver recipient without candidemia.

Analysis of spontaneous resolution of cytomegalovirus replication after transplantation in CMV-seropositive patients with pretransplant CD8+IFNG+ response.

All-oral direct-acting antiviral therapy against hepatitis C virus (HCV) in human immunodeficiency virus/HCV-coinfected subjects in real-world practice: Madrid coinfection registry findings.

Infective Endocarditis in Patients With Bicuspid Aortic Valve or Mitral Valve Prolapse.

Effects of HIV, antiretroviral therapy and prebiotics on the active fraction of the gut microbiota.

High HIV seroconversion rate in hepatitis C virus-infected drug users followed in a harm reduction unit: a lost opportunity for preexposure prophylaxis.

Dolutegravir and rilpivirine for the maintenance treatment of virologically suppressed HIV-1 infection.

Lack of evidence of association between IFNG and IL28B polymorphisms and QuantiFERON-CMV test results in seropositive transplant patients.

ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Intracellular signaling pathways: tyrosine kinase and mTOR inhibitors).

Deep-Sequencing Analysis of the Dynamics of HIV-1 Quasiespecies in Naive Patients during a Short Exposure to Maraviroc.

Treatment and prevention of invasive pneumococcal disease.

Elevated liver stiffness is linked to increased biomarkers of inflammation and immune activation in HIV/hepatitis C virus-coinfected patients.

Barriers to health care services for migrants living with HIV in Spain.

Overcoming Barriers to HIV Prevention and Healthcare Among Sub-Saharan African Migrants in Spain.

Increased prevalence of asymptomatic vertebral fractures in HIV-infected patients over 50 years of age.

Maraviroc Is Associated with Latent HIV-1 Reactivation through NF-?B Activation in Resting CD4 + T Cells from HIV-Infected Individuals on Suppressive Antiretroviral Therapy.